Second Time A Charm? Enzon Sells Biotech Business To Italian Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
One year after a failed effort to sell off its biotech business, Enzon will bring in $300 million by selling its four specialty drugs to Sigma-Tau.